The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Open accessAbstract
BACKGROUND: Tuberculosis is the world's leading infectious disease killer. We aimed to identify shorter, safer drug regimens for the treatment of tuberculosis. METHODS: We did a randomised controlled, open-label trial with a multi-arm, multi-stage design. The trial was done in seven sites in South Africa and Tanzania, including hospitals, health centres, and clinical trial centres. Patients with newly diagnosed, rifampicin-sensitive, previously untreated pulmonary tuberculosis were randomly assigned in a 1:1:1:1:2 ratio to receive (all orally) either 35 mg/kg rifampicin per day with 15-20 mg/kg ethambutol, 20 mg/kg rifampicin per day with 400 mg moxifloxacin, 20 mg/kg rifampicin per day with 300 mg SQ109, 10 mg/kg rifampicin per day with 300 mg SQ109, or a daily standard control regimen (10 mg/kg rifampicin, 5 mg/kg isoniazid, 25 mg/kg pyrazinamide, and 15-20 mg/kg ethambutol). Experimental treatments were given with oral 5 mg/kg isoniazid and 25 mg/kg pyrazinamide per day for 12 weeks, followed by 14 weeks of 5 mg/kg isoniazid and 10 mg/kg rifampicin per day. Because of the orange discoloration of body fluids with higher doses of rifampicin it was not possible to mask patients and clinicians to treatment allocation. The primary endpoint was time to culture conversion in liquid media within 12 weeks. Patients without evidence of rifampicin resistance on phenotypic test who took at least one dose of study treatment and had one positive culture on liquid or solid media before or within the first 2 weeks of treatment were included in the primary analysis (modified intention to treat). Time-to-event data were analysed using a Cox proportional-hazards regression model and adjusted for minimisation variables. The proportional hazard assumption was tested using Schoelfeld residuals, with threshold p<0·05 for non-proportionality. The trial is registered with ClinicalTrials.gov (NCT01785186). FINDINGS: Between May 7, 2013, and March 25, 2014, we enrolled and randomly assigned 365 patients to different treatment arms (63 to rifampicin 35 mg/kg, isoniazid, pyrazinamide, and ethambutol; 59 to rifampicin 10 mg/kg, isoniazid, pyrazinamide, SQ109; 57 to rifampicin 20 mg/kg, isoniazid, pyrazinamide, and SQ109; 63 to rifampicin 10 mg/kg, isoniazid, pyrazinamide, and moxifloxacin; and 123 to the control arm). Recruitment was stopped early in the arms containing SQ109 since prespecified efficacy thresholds were not met at the planned interim analysis. Time to stable culture conversion in liquid media was faster in the 35 mg/kg rifampicin group than in the control group (median 48 days vs 62 days, adjusted hazard ratio 1·78; 95% CI 1·22-2·58, p=0·003), but not in other experimental arms. There was no difference in any of the groups in time to culture conversion on solid media. 11 patients had treatment failure or recurrent disease during post-treatment follow-up: one in the 35 mg/kg rifampicin arm and none in the moxifloxacin arm. 45 (12%) of 365 patients reported grade 3-5 adverse events, with similar proportions in each arm. INTERPRETATION: A dose of 35 mg/kg rifampicin was safe, reduced the time to culture conversion in liquid media, and could be a promising component of future, shorter regimens. Our adaptive trial design was successfully implemented in a multi-centre, high tuberculosis burden setting, and could speed regimen development at reduced cost. FUNDING: The study was funded by the European and Developing Countries Clinical Trials partnership (EDCTP), the German Ministry for Education and Research (BmBF), and the Medical Research Council UK (MRC).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“improving upon first-generation inhibitors such as SQ109, which is in phase 2 clinical trials (158)”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [158]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fox, W., Ellard, G. A., & Mitchison, D. A. (1999) · PubMed · Cited by 797
Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
Gillespie, S. H., Crook, A. M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murray, S. R., Pappas, F., Phillips, P. P. J., & Nunn, A. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407426 · Cited by 645
Self-citationThe association between sterilizing activity and drug distribution into tuberculosis lesions
Prideaux, B., Via, L. E., Zimmerman, M. D., Eum, S., Sarathy, J., O'Brien, P., Chen, C., Kaya, F., Weiner, D. M., Chen, P.-Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3937 · Cited by 461
Clinical Pharmacokinetics of Rifampicin
Acocella, G. (1978) · Clinical Pharmacokinetics · doi:10.2165/00003088-197803020-00002 · Cited by 405
Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin
Gumbo, T., Louie, A., Deziel, M. R., Liu, W., Parsons, L. M., Salfinger, M., & Drusano, G. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01533-06 · Cited by 345
Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis
Jayaram, R., Gaonkar, S., Kaur, P., Suresh, B. L., Mahesh, B. N., Jayashree, R., Nandi, V., Bharat, S., Shandil, R. K., Kantharaj, E., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2118-2124.2003 · Cited by 335
Rustomjee, R., Lienhardt, C., Kanyok, T. P., Davies, G., Levin, J., Mthiyane, T., Reddy, C., Sturm, A. W., Sirgel, F. A., Allen, J., et al. (2008) · PubMed · Cited by 326
Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis
Heemskerk, A. D., Bang, N. D., Mai, N. T. H., Chau, T. T. H., Phu, N. H., Loc, P. P., Chau, N. V. V., Hien, T. T., Dung, N. H., Lan, N. T. N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507062 · Cited by 310
A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
Boeree, M. J., Diacon, A. H., Dawson, R., Narunsky, K., du Bois, J., Venter, A., Phillips, P. P. J., Gillespie, S. H., McHugh, T. D., Hoelscher, M., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201407-1264oc · Cited by 309
Self-citationConde, M. B., Efron, A., Loredo, C., De Souza, G. R. M., Graça, N. P., Cezar, M. C., Ram, M., Chaudhary, M. A., Bishai, W. R., Kritski, A. L., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60333-0 · Cited by 289
Research works printed but not linked: 1
- Boeree MJ. High-dose rifampicin: issues in efficacy and safety. The 46th Union World Conference on Lung Health; Cape Town; Dec 6, 2015.
Cited by
Furin, J., Cox, H., & Pai, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30308-3 · Cited by 873
Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30079-6 · Cited by 684
Self-citationDrain, P. K., Bajema, K. L., Dowdy, D., Dheda, K., Naidoo, K., Schumacher, S. G., Ma, S., Meermeier, E., Lewinsohn, D. M., & Sherman, D. R. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00021-18 · Cited by 565
on behalf of the Tuberculous Meningitis International Research Consortium, Wilkinson, R. J., Rohlwink, U., Misra, U. K., van Crevel, R., Mai, N. T. H., Dooley, K. E., Caws, M., Figaji, A., Savic, R., et al. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.120 · Cited by 508
Tiberi, S., du Plessis, N., Walzl, G., Vjecha, M. J., Rao, M., Ntoumi, F., Mfinanga, S., Kapata, N., Mwaba, P., McHugh, T. D., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30110-5 · Cited by 396
Metadata
- Authors
- Boeree, M. J., Heinrich, N., Aarnoutse, R., Diacon, A. H., Dawson, R., Rehal, S., Kibiki, G. S., Churchyard, G., Sanne, I., Ntinginya, N. E., Minja, L. T., Hunt, R. D., Charalambous, S., Hanekom, M., Semvua, H. H., Mpagama, S. G., Manyama, C., Mtafya, B., Reither, K., Wallis, R. S., Venter, A., Narunsky, K., Mekota, A., Henne, S., Colbers, A., van Balen, G. P., Gillespie, S. H., Phillips, P. P. J., & Hoelscher, M.
- Affiliations
- Radboud University Medical Center (NL)
- German Center for Infection Research (DE)
- Stellenbosch University (ZA)
- University of Cape Town (ZA)
- MRC Clinical Trials Unit at UCL (GB)
- Tumaini University (TZ)
- University of the Witwatersrand (ZA)
- Helen Joseph Hospital (ZA)
- National Institute for Medical Research (TZ)
- Ifakara Health Institute (TZ)
- University College London (GB)
- Aurum Institute (ZA)
- Swiss Tropical and Public Health Institute (CH)
- Ludwig-Maximilians-Universität München (DE)
- University of St Andrews (GB)
- Corresponding author
- Boeree, Martin J
- ORCID
- Boeree, Martin J
- Heinrich, Norbert
- Aarnoutse, Rob
- Diacon, Andreas H
- Dawson, Rodney
- Rehal, Sunita
- Kibiki, Gibson S
- Churchyard, Gavin
- Sanne, Ian
- Ntinginya, Nyanda E
- Minja, Lilian T
- Hunt, Robert D
- Charalambous, Salome
- Hanekom, Madeleine
- Semvua, Hadija H
- Mpagama, Stellah G
- Mtafya, Bariki
- Reither, Klaus
- Wallis, Robert S
- Narunsky, Kim
- Colbers, Angela
- Gillespie, Stephen H
- Phillips, Patrick P J
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 17
- Issue
- 1
- Pages
- 39-49
- ISSN
- 1473-3099 (ISSN-L)
- PMC
- PMC5159618
- OpenAlex
- W2543303947
- Cited by
- 379
- References
- 31
- Citations by year
- 2026: 18 · 2025: 36 · 2024: 28 · 2023: 40 · 2022: 41 · 2021: 43 · 2020: 40 · 2019: 53 · 2018: 47 · 2017: 32
- FWCI
- 40.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet Infectious Diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IHI Repository (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- St Andrews Research Repository (St Andrews Research Repository) (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Medical Research Council (MC_UU_12023/27)
- European and Developing Countries Clinical Trials Partnership
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- pulmonary tuberculosis, rifampicin, moxifloxacin, SQ109, linezolid, ethambutol, isoniazid, pyrazinamide, culture conversion, rifampicin resistance, treatment time reduction, drug safety, adverse events, South Africa, Tanzania
- MeSH terms
- Moxifloxacin, Adamantane, Adult, Antitubercular Agents, Drug Administration Schedule, Drug Therapy, Combination, Ethambutol, Ethylenediamines, Female, Humans, Isoniazid, Male, Pyrazinamide, Rifampin, South Africa, Tanzania, Tuberculosis, Pulmonary, Fluoroquinolones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. https://app.cochat.ai/papers/10.1016/s1473-3099(16)30274-2
- The paper
- Boeree, M. J., Heinrich, N., Aarnoutse, R., Diacon, A. H., Dawson, R., Rehal, S., Kibiki, G. S., Churchyard, G., Sanne, I., Ntinginya, N. E., Minja, L. T., Hunt, R. D., Charalambous, S., Hanekom, M., Semvua, H. H., Mpagama, S. G., Manyama, C., Mtafya, B., Reither, K., . . . Hoelscher, M. (2017). High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(16)30274-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.